NCT Number: NCT01500499
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies the role of biomarkers in disease progression in samples from patients with acute myeloid leukemia.
Looking for future studies?
Notify MeKey information
Conditions
Age range
Up to 30 year
Sex eligibility
All sexes
Study type
Observational
About this study
OBJECTIVES:
- To determine the subcellular localization of the MLL-AF1q fusion protein in leukemia cells.
OUTLINE: Cryopreserved specimens are analyzed for MLL-AF1q fusion protein and AF1 gene expression by mass spectrometry, western blot analysis, semi-quantitative PCR, and qPCR.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
DISEASE CHARACTERISTICS:
- Cryopreserved acute myeloid leukemia specimens
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Treatment and study plan
gene rearrangement analysis
Geneticpolymerase chain reaction
Geneticprotein analysis
Geneticwestern blotting
Geneticlaboratory biomarker analysis
Othermass spectrometry
OtherPrimary outcomes
-
Subcellular localization of the MLL-AF1q fusion protein in leukemia cells
Sponsors and collaborators
Lead sponsor
Children's Oncology Group
Network
Collaborators
- National Cancer Institute (NCI)
Registry information
Official study title
The Role of AF1q in Progression of Leukemia
Important dates
- Study start
- 2011
- Primary completion
- 2016
- First posted
- Dec 28, 2011
- Registry last updated
- May 18, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
NCT00081874
Bone Marrow Diseases, Chronic Disease
Houston, Texas, United States
View Trial DetailsA Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
NCT02158858
Blood Coagulation Disorders, Blood Platelet Disorders
Phoenix, Arizona, United States
View Trial DetailsBusulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
NCT00534430
Anemia, Anemia, Refractory
View Trial DetailsTocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
NCT03434730
Acute Leukemia, Acute Lymphoblastic Leukemia
New York, United States
View Trial Details